CLINICAL TRIALS PROFILE FOR LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
✉ Email this page to a colleague
All Clinical Trials for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001724 ↗ | Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | 1997-11-01 | This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery. |
| NCT00107822 ↗ | Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children | Completed | ZARS Pharma Inc. | Phase 3 | 2005-04-01 | The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure. |
| NCT00107835 ↗ | Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults | Completed | ZARS Pharma Inc. | Phase 3 | 2005-05-01 | The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure. |
| NCT00154167 ↗ | Safety and Efficacy Study of NV-101 in Dental Patients | Completed | Novalar Pharmaceuticals, Inc. | Phase 2 | 2003-02-01 | The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101 |
| NCT00194610 ↗ | Botox as a Treatment for Interstitial Cystitis in Women | Completed | Paul G. Allen Family Foundation | Phase 4 | 2004-05-01 | Patients with interstitial cystitis have been well documented to have pelvic floor muscle tenderness as well as pain on bladder distension. Some investigators have even suggested that pelvic floor muscle pain is primarily the cause of bladder problems. Botulinum toxin A causes muscle relaxation by inhibiting the acetylcholine release at the neuromuscular junction. It has been shown that this mechanism relieves pain in a number of muscle spasm-related syndromes. Because, at present, there is little effective therapy available for patients with interstitial cystitis, the researchers want to determine if botulinum toxin A will relieve bladder and pelvic pain in these patients. |
| NCT00194610 ↗ | Botox as a Treatment for Interstitial Cystitis in Women | Completed | University of Washington | Phase 4 | 2004-05-01 | Patients with interstitial cystitis have been well documented to have pelvic floor muscle tenderness as well as pain on bladder distension. Some investigators have even suggested that pelvic floor muscle pain is primarily the cause of bladder problems. Botulinum toxin A causes muscle relaxation by inhibiting the acetylcholine release at the neuromuscular junction. It has been shown that this mechanism relieves pain in a number of muscle spasm-related syndromes. Because, at present, there is little effective therapy available for patients with interstitial cystitis, the researchers want to determine if botulinum toxin A will relieve bladder and pelvic pain in these patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
Condition Name
Clinical Trial Locations for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
Trials by Country
Clinical Trial Progress for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
Clinical Trial Phase
Clinical Trial Sponsors for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
Sponsor Name
